Psychemedics Corp (PMDI)

Psychemedics Corporation is a clinical laboratory service provider that specializes in testing hair samples to detect drugs of abuse. The company’s patented technology offers employers, law enforcement, schools, treatment professionals, and parents a method to screen for substance use that captures a much longer historical window than conventional testing — up to 90 days of drug use can be detected in a single hair sample, whereas urine or blood tests typically show only days of recent use.

Hair acts like a tape recorder: it records drugs in proportion to use as they deposit in the cortex during growth.

The science behind the method

The technology works on a straightforward biological principle. When a person ingests drugs, the metabolites — the chemicals the body produces as it processes those substances — circulate in the bloodstream and deposit in the cortex of growing hair. Because hair grows steadily and the deposits remain permanently embedded, the hair sample becomes a chronological record. A sample three inches long captures roughly 90 days of use at the scalp, while longer sections extend the window further back in time. This historical depth is what distinguishes hair testing from urine or blood testing, which detect only recent consumption.

The company’s laboratories use mass spectrometry to confirm the presence of specific substances: cocaine, marijuana, PCP, amphetamines including methamphetamine and MDMA, opioids ranging from heroin metabolite to prescription painkillers, synthetic cannabinoids, benzodiazepines, and others. The test also reports quantitative information — an approximate measure of how much drug was consumed — and can reveal patterns of escalating or declining use.

Origins and the hair-testing pioneer

Psychemedics was founded in 1986 by Dr. Werner Baumgartner, a chemist who spent years researching whether drugs could be reliably detected in hair samples. Baumgartner became a nationally recognized expert in this field; his credentials were boosted by a famous demonstration in which he analyzed hair strands from the 19th-century poet John Keats. Despite the age of the samples, Baumgartner detected increasing amounts of opium in the poet’s hair, consistent with Keats taking stronger painkillers before his death from tuberculosis at 26 — a finding that captured scientific and public attention.

The company incorporated in Santa Monica, California in 1986 and pioneered the first commercially available hair-drug-testing service. It brought the technology into markets where employers, testing facilities, and law enforcement saw value: banks, manufacturers, retailers, mining operations, hotels, casinos, and government agencies. The company expanded through the 1990s and 2000s as workplace drug testing became standard practice across regulated industries and many others.

The business model and customer base

Psychemedics operates a simple, asset-efficient model: it receives hair samples from customers, processes them at centralized laboratory facilities, and returns results through secure channels. Revenue is generated per sample tested, which gives the company recurring income from its customer base as they conduct ongoing hiring, periodic monitoring, and compliance testing.

The company’s customers span multiple markets. Employers use the service for pre-employment screening and random employee testing as part of safety and compliance programs. Law enforcement and courts rely on the test for investigations and probation monitoring. Treatment professionals and rehabilitation centres use it to monitor patients’ progress. Schools and parents use it for substance monitoring. This diversified customer base insulates the business from reliance on any single sector.

Competitive position and regulatory standing

Psychemedics holds FDA clearance for its testing procedures and maintains CAP (College of American Pathologists) laboratory certification. These credentials certify that its methods are reliable, that its results are court-admissible, and that the company meets rigorous quality standards. The historical depth of hair testing gives Psychemedics an inherent advantage: no competitor can offer the 90-day window through urine or blood tests, and while other hair-testing labs exist, Psychemedics has established itself as the largest and most widely recognized provider.

The regulatory environment supports the use of hair testing in employment and legal contexts. Many states and federal agencies explicitly permit hair testing, and some require it in particular industries such as transportation and nuclear power. The company’s standing in these regulated sectors provides durable demand.

Recent changes and current position

As of 2026, Psychemedics transitioned from the Nasdaq exchange to over-the-counter trading, moving from ticker PMD to PMDI. This shift reflects the company’s position as a smaller, profitable operating business rather than a growth stock. The company maintains laboratory operations in Culver City, California, and has consolidated its headquarters to Acton, Massachusetts.

The business faces pressure from competing testing modalities — some employers prefer saliva or urine tests for convenience — and from increasing automation in hiring, which can reduce the volume of traditional drug testing. However, the 90-day window and legal admissibility of results provide a defensible niche, particularly in safety-sensitive industries where regulators mandate comprehensive testing.

How to research Psychemedics

Investors interested in the company should review its annual 10-K filing (SEC CIK 0000806517) for details on revenue by customer segment, laboratory utilization rates, and pricing trends. The OTC markets provide less frequent disclosures than Nasdaq, so quarterly earnings releases and management commentary on customer activity become more important signals. Watch for changes in customer retention, turnaround times, and pricing power — all indicators of competitive strength. The company’s ability to hold margins as a low-volume, niche provider on a smaller exchange is the core question for the business.